← All indications
Extensively Drug-Resistant Tuberculosis
Tuberculosis resistant to ISONIAZID and RIFAMPIN and at least three of the six main classes of second-line drugs (AMINOGLYCOSIDES; polypeptide agents; FLUOROQUINOLONES; THIOAMIDES; CYCLOSERINE; and PARA-AMINOSALICYLIC ACID) as defined by the CDC.
Drugs by status
Approved for this indication (2)
Phase 4 trials (1)
Organizations
Organization Involved with Phase 4 Indications (1)
Organization Involved with Phase 3 Indications (20)
- Global Alliance for TB Drug Development
- World Health Organization
- University of London
- University of Limpopo
- University of Liverpool
- University of California, San Francisco
- University of Cape Town
- University of Basel
- University of the Witwatersrand
- Drugs for Neglected Diseases Initiative
- Stellenbosch University
- TB & HIV Investigative Network (THINK)
- Walter Sisulu University
- Government of Belarus
- Government of Uzbekistan
- ERT Clinical
- Hackensack University Medical Center
- Medecins Sans Frontieres
- Wits Health Consortium (Pty) Ltd
- Republican Research and Practical Centre for Pulmonology and Tuberculosis
Organization Involved with Phase 2 Indications (10)